retatrutide type 2 diabetes trial nct Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA A new clinical trial from

Both the LEADER (liraglutide) and SUSTAIN-6 (subcutaneous semaglutide) trials reported significant reductions in the primary outcome (incidence of MACE)

If youre ready to explore how dermal fillers can benefit you throughout your weight loss journey, our MFI team would love to guide you through your options

Incorporate a liposomal glutathione supplement into your morning routine

Its role in oral melanoma is being studied

These discussions highlight real barriers to medication access that dont exist in US-focused forums, making Canadian perspectives particularly valuable for understanding practical treatment challenges